Bausch + Lomb Corporation: Business Overview, Financials & Competitive Analysis
Bausch + Lomb Corporation scores 5/10 on the AskCyborg Cyborg Score (Mixed). Ambitious transformation plan with significant pipeline upside offset by near-term financial distress signals and moderate stock performance momentum. Bausch Lomb has over 59% chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading.
What is Bausch + Lomb Corporation's industry? Bausch + Lomb Corporation (bausch.com) operates in Eye Health / Ophthalmic Medical Devices & Pharmaceuticals. AskCyborg classifies Bausch + Lomb Corporation under Eye Health / Ophthalmic Medical Devices & Pharmaceuticals in its company registry.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a leading global eye health company that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth thro...
Cyborg Score thesis
Ambitious transformation plan with significant pipeline upside offset by near-term financial distress signals and moderate stock...
Read the full analyst-debate transcript →Get the Latest Bausch + Lomb Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBausch + Lomb Corporation Overview
Pro stress-test →Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a leading global eye health company that is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. The company operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals.
Strategic Profile
Pro stress-test →At its November 2025 investor day, management outlined a three-year transformation plan targeting 5–7% constant currency revenue CAGR through 2028, ~23% adjusted EBITDA margin in 2028, and double-digit adjusted annual EPS growth from 2026–2028. The company projects total peak sales of pipeline products of approximately $7 billion with multiple product launches across Consumer, Pharmaceuticals, Surgical, and Contact Lens businesses spanning 2026–2031.
Competitive Landscape
Pro stress-test →Alcon is one of Bausch + Lomb's main competitors in the eye health space. The company competes with integrated eye care providers offering contact lenses, pharmaceuticals, and surgical devices. B&L's competitive advantage lies in its comprehensive product portfolio and global scale, though execution on pipeline and debt reduction will be critical for long-term positioning.
Industry Context
Bausch + Lomb Corporation operates in Eye Health / Ophthalmic Medical Devices & Pharmaceuticals.
Key facts
Founded: 1853 · Headquarters: Vaughan, Canada · Employees: 13,500 · Revenue: $4.98B · Market cap: $6.19B